ALK-Abelló: Assessing Valuation After 2025 Results and 2026 Guidance

Published: February 28, 2026

ALK-Abelló (CPSE:ALK B) has garnered investor interest following the release of its full-year 2025 results, the issuance of 2026 guidance and a leadership change within its Research and Development (R&D) department, tied to its Allergy+ strategy. Recent market sentiment has shifted positively, with a one-day share price increase of 4.95%, contrasting with a one-year total shareholder return of 43.96% and a three-year return of 106.95%.

Current Valuation and Analyst Perspectives

The stock currently trades at approximately 11% below one intrinsic value estimate and 16% below analyst targets, prompting questions about potential buying opportunities. As of February 28, 2026, ALK-Abelló’s closing price is DKK220.4, while the widely followed narrative fair value stands at DKK255, suggesting potential upside.

Growth Drivers

Key growth drivers include the expansion of ALK-Abelló’s dedicated pediatric sales force in North America and strategic partnerships, such as the collaboration with ARS Pharma. Broadening approval for pediatric use is expected to accelerate novel patient growth and increase sales volume of high-margin tablet products.

Financial Performance and Forecasts

Analysts forecast earnings and revenue growth of 14.5% and 11.3% per annum, respectively. Earnings per share (EPS) is projected to grow by 14.1% annually, with a forecasted return on equity of 18.7% in three years. Simply Wall Street provides detailed future growth analysis.

Dividend Announcement

ALK-Abelló A/S has announced an annual dividend, payable on March 19, 2026. Simply Wall Street reports on this dividend information.

Potential Risks and Considerations

While the outlook is positive, potential risks include slower uptake of new products like EURneffy or pediatric tablets than analysts anticipate, and R&D and capacity spending exceeding sales growth. The current Price-to-Earnings (P/E) ratio of 40.8x is above the European pharmaceuticals average of 24.1x and an estimated fair ratio of 16.6x, indicating a premium potentially baked into the price.

Key Takeaways

• ALK-Abelló demonstrates strong long-term shareholder returns (43.96% over one year, 106.95% over three years).
• The stock is currently trading below both intrinsic value and analyst price targets.
• Growth is driven by pediatric allergy treatments, strategic partnerships, and product innovation.
• Investors should consider the premium valuation and potential risks associated with new product uptake and R&D spending.

Investors are encouraged to conduct thorough due diligence and consider their own financial objectives before making any investment decisions.